6-Hydroxydopamine infusions into the structures of mesolimbic dopaminergic system alter the memory enhancing effect of CK-8US and caerulein in rats.
The influence of bilateral destruction of dopaminergic endings in the anterior and in the posterior part of nucleus accumbens (NAS) and in the nucleus septi lateralis (NSL), by 6-hydroxydopamine (6-OHDA) infusions, on the facilitatory effect of cholecystokinin-unsulfated octapeptide (CCK-8US) and caerulein (CER) on memory motivated affectively was investigated in male Wistar rats. CCK-8US and CER were given s.c. at the doses of 10 microg/kg and 0.5 microg/kg respectively, immediately after a single learning trial in a passive avoidance situation, ten days after bilateral 6-OHDA lesions (desipramine pre-treatment; 25 mg/kg, i.p.) of these structures. Bilateral 6-OHDA lesions to the anterior and to the posterior part of NAS totally abolished and significantly attenuated, respective, the facilitatory effect of CCK-8US and CER on retention of a passive avoidance behaviour evaluated 24 h later, while bilateral lesions to NSL did not have any influence on it. Moreover, neither, destruction of dopaminergic endings in lesioned structures, nor application of CCK-8US and CER changed the spontaneous psychomotor activity of rats estimated in an "open field" test. These results may indicate that dopaminergic projection to the anterior part of NAS is mainly responsible for the facilitatory effect of CCK-8US and CER on memory motivated affectively.
Winnicka
M M
MM
Department of General and Experimental Pathology, Medical Academy, Białystok, Poland. mmw@amb.edu.pl
Hryniewicz
A
A
Bialuk
I
I
Wiśniewski
K
K
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology; D002108:Ceruletide / Q000494:pharmacology*; D003714:Denervation; D004298:Dopamine / Q000502:physiology; D008032:Limbic System / Q000502:physiology*; D008297:Male; D008568:Memory / Q000187:drug effects* / Q000502:physiology; D016627:Oxidopamine; D051381:Rats; D017208:Rats, Wistar; D012844:Sincalide / Q000494:pharmacology*; D013565:Sympatholytics
D013565:Sympatholytics; D002108:Ceruletide; D016627:Oxidopamine; D012844:Sincalide; D004298:Dopamine